FDA Commissioner's 3,500x Overstatement: The Autism Drug That Helps 70 Children, Not Hundreds of Thousands

To understand the magnitude of Makary's overstatement, it is necessary to understand what CFD-FOLR1 actually is — and how different it is from autism. Cerebral folate transport deficiency (CFD-FOLR1) is an autosomal recessive neurological disorder caused by loss-of-function mutations in the FOLR1 gene, which produces folate receptor alpha, a protein that transports folate across the choroid plexus and into cerebrospinal fluid. When both copies of FOLR1 are mutated, folate cannot reach the brain even if systemic folate levels are normal. ^[20][21]

The condition is vanishingly rare. Peer-reviewed prevalence data from NCBI GeneReviews documents more than 35 confirmed cases from 32 families reported in the literature to date, consistent with outside estimates that the disorder affects roughly 1 in a million people. Applied to the U.S. child population, this is consistent with the FDA's own estimate that roughly 70 children in the U.S. are eligible for the approved indication. ^[1][20]

Treatment with high-dose oral leucovorin is effective for this specific indication: among the 27 patients in the FDA's review who received oral leucovorin only, 24 (89%) showed "a range of clinical improvements" in neurological symptoms, per the FDA label. The mechanism is receptor-bypass: leucovorin (5-formyltetrahydrofolate) does not rely on the FOLR1 receptor — it enters cells via a different pathway. This only helps when the FOLR1 receptor is the problem. ^[4]

The critical disconnect: Most autistic children do not have FOLR1 mutations; they have normally functioning folate transport, so giving them leucovorin does not address any underlying mechanism specific to their condition. The "folate receptor autoantibody" theory Makary invoked — that immune antibodies block the FOLR1 receptor in autistic children without a genetic mutation — remains unproven, and autism-unaffected siblings of autistic children have been found to show similar antibody levels, undermining a causal link to autism. ^[8]

Dr. David Mandell of the University of Pennsylvania put it plainly: "We have nothing resembling even moderate evidence that leucovorin is an effective treatment for autism symptoms." ^[8]

The scientific basis for Makary's September claims was already collapsing before the March 2026 approval. In January 2026 — while the FDA was still conducting its review — the largest randomized controlled trial on leucovorin and autism was retracted. The trial, published in September 2024 in the European Journal of Pediatrics, involved 77 children and was led by Prateek Kumar Panda at the All India Institute of Medical Sciences. ^[6][17]

The retraction notice confirmed the journal's editor "no longer has confidence in the validity of the results and conclusions," after reviewers identified data errors and were "unable to replicate the results reported in the article from the dataset provided." Only two of the study's six authors agreed to the retraction; the other four did not respond. ^[6][17]

Expert reactions were unsparing. Dr. Thomas Challman stated: "The retraction of this paper removes a significant portion of the already weak evidence supporting the value of folinic acid as a treatment for autism." Dr. Dorothy Bishop called the overall research quality "uniformly poor," saying of this study's statistics that they were "all over the place." Dr. Shafali Jeste noted the drug's prominence was "because of the publicity around it, not because we as scientists believe that this is the drug that we should be testing." ^[6]

The remaining evidence base consists of a handful of small studies, most originating from the same research group; the largest non-retracted trial identified in reporting enrolled 48 children. No large multicenter Phase 3 randomized controlled trial has ever been completed. The American Academy of Pediatrics' interim guidance, published in fall 2025, noted that all the leucovorin-autism studies involve fewer than 100 patients, that most originate from "the same group of researchers," and that no large Phase 3 trial exists. ^[22][23]

The authority of the FDA Commissioner's office did not merely spread misinformation — it produced a measurable real-world response. A study published in The Lancet by researchers at Brown University and Harvard Medical School, including Dr. Michael Barnett and Dr. Jeremy Faust, found that outpatient leucovorin prescriptions for children ages 5–17 were 71% higher than expected in the months following the White House briefing, with prescribing more than doubling within the first weeks. ^[3]

This surge mattered because leucovorin also has a decades-long use in oncology, given alongside chemotherapy drugs like 5-fluorouracil as part of the FOLFOX and FOLFIRI regimens for colorectal and other cancers. The autism-driven demand for the oral tablet form competed with a drug already prone to periodic shortages. Reporting on the oncology side was more nuanced than the shortage headlines suggested, however: because cancer treatment relies primarily on the intravenous form of leucovorin, which manufacturers reportedly prioritized, it was not clearly established that chemotherapy patients faced significant disruption — even as the oral-tablet shortage itself was real and FDA-documented. ^[24][25]

By December 2025, the FDA issued a "Dear Provider" letter authorizing emergency imports of leucovorin tablets from Canada and Spain to help ease shortfalls. CVS Health spokesperson Roslyn Guarino confirmed: "We are seeing supply challenges among certain versions of generic leucovorin." ^[24]

Families of autistic children were also affected by the gap between the September rhetoric and the March outcome. CNN reported in early March 2026 that parents were scrambling to find the drug amid growing shortages. Alycia Halladay of the Autism Science Foundation described the difference between the September announcement and the March approval as "1,000% different," noting: "The bell has been rung, and we've already seen through the data that prescriptions for leucovorin have skyrocketed." ^[7][24]

The AAP's interim guidance also flagged safety risks in the off-label prescribing surge: high-dose folinic acid can mask the hematologic signs of vitamin B12 deficiency while neurological damage continues, and leucovorin is contraindicated in MTHFS (5,10-methenyltetrahydrofolate synthetase) deficiency, a separate metabolic disorder in which folinic acid cannot be processed. ^[22]

The leucovorin-autism theory traces largely to one researcher: Dr. Richard Frye, a child neurologist now at the Rossignol Medical Center in Phoenix, Arizona. Frye's 2012 Molecular Psychiatry study reported folate receptor antibodies in 70 of 93 autistic patients tested in his clinic, providing the statistical basis Makary drew on for his "20 to 50%" claim. ^[19]

Frye's conflicts of interest are substantial. He is a consultant to Neuroneeds, which markets the "Spectrum Needs" supplement, and authored a self-published book, The Folate Fix. A 2006 case report he co-authored failed to disclose that the subject was the daughter of lead author Jon Poling, a conflict the journal's editor later called "an appallingly troubling issue." His first NIH-supported leucovorin trial, at Arkansas Children's Hospital, was suspended by the FDA in 2015 for compliance violations posing "unreasonable and significant risk of illness or injury to human subjects." His second, NIH-funded multicenter trial remains unpublished after Phoenix Children's Hospital terminated him in 2022. ^[19]

Frye's own response to the White House announcement was telling: "For the administration to come through and say there is a treatment for autism is a major turning point. Could they have given some more nuance to it? Sure." On the institutional resistance his research faced: "It is rich that the NIH and Big Pharma want to take over leucovorin when they and the universities have fought my research for 20 years." Frye has also linked his interest in the drug to his belief that vaccines can injure children: "Several times a year when I used to do the hospital thing, I'd have a child come in that was injured by a vaccine." ^[19][30]

Commissioner Makary himself disclosed significant financial ties at the time of his confirmation, including a board director role at Harrow, an ophthalmic pharmaceuticals company ($40,000 in compensation in 2023); chief medical officer at Sesame, a telehealth company offering compounded GLP-1 medications; and advisory roles with Paragon Health Institute, Sidecar Health, and Nava. Makary was confirmed as FDA Commissioner by a 56-44 Senate vote in March 2025. ^[18][29]

The professional scientific community pushed back on the administration's framing quickly. The AAP published interim guidance in fall 2025 — within weeks of the White House briefing — declining to recommend leucovorin for routine autism use and specifically citing insufficient patient numbers, concentration of research in one group, absence of independent replication, B12-masking risk, and the MTHFS contraindication. JAMA covered the guidance. ^[22][23]

The leucovorin episode is not an isolated scientific error; it fits a broader pattern in the "Make America Healthy Again" (MAHA) agenda being executed jointly by RFK Jr. and Makary at HHS/FDA, as journalists covering the agency have described it. ^[9][10]

Step 1 — A fringe medical theory with enough published literature to provide scientific cover: leucovorin and folate receptor autoantibodies, backed by Dr. Frye's research.

Step 2 — A favored researcher elevated, whose work aligns with the administration's anti-establishment narrative. Dr. Frye fit, having spent two decades describing himself as fighting "NIH and Big Pharma."

Step 3 — A dramatic public announcement from the White House, generating hope and political capital among autism parents and anti-establishment health consumers.

Step 4 — The FDA review runs its course after the political messaging has already done its work: prescriptions surge, and the announcement is treated by the public as settled fact.

Step 5 — The actual approval narrows to a defensible scientific subset, with far less press coverage than the original announcement.

The FDA's own September 22, 2025 press release — titled "FDA Takes Action to Make Treatment Available for Autism Symptoms" — used language that implied broader coverage than what was ultimately delivered; the described Medicaid coverage for the ASD indication was never fulfilled. ^[27]

Reporting has captured how career staff experienced this dynamic: the Genetic Literacy Project, in a February 2026 investigation, described "one veteran" describing the agency's culture as "go find data to support this, go find data to support that" — a reversal of the normal evidence-to-approval process. The same investigation quoted former FDA official Henry Miller, who spent 15 years at the agency: "At RFK, Jr.'s FDA, scientific caution and rigor now matter less than political messaging and wishful thinking." ^[9]

GSK's response to receiving the CFD-FOLR1 approval is telling: the company confirmed it does not intend to manufacture or market Wellcovorin again, having discontinued the branded drug in 1997. No major pharmaceutical manufacturer appears to have sought to commercially capitalize on the episode. ^[5]

The leucovorin case represents a distinct form of health misinformation: the government official as originating source. Standard misinformation models trace false claims from fringe sources through social media toward mainstream credibility; here, the FDA Commissioner was the source, which complicates the normal fact-checking hierarchy. ^[1]

The episode sits alongside a broader pattern at the FDA under Kennedy's HHS. In January 2026, the FDA quietly removed a consumer webpage that had warned against dangerous purported autism treatments — including chelation therapies, hyperbaric oxygen therapy, detoxifying clay baths, raw camel milk, and chlorine dioxide (MMS) — with HHS telling ProPublica the removal happened "during a routine clean up of dated content at the end of 2025." No autism advocacy group supported the removal; the Autistic Self Advocacy Network's Zoe Gross said such warnings remained necessary because "people are still being preyed on by these alternative treatments." The CDC separately overhauled its vaccine-autism webpage to suggest studies supporting a link "have been ignored by health authorities." ^[14][26]

Who bears the harm from this episode: Parents of autistic children were encouraged to pursue an unproven drug ahead of the evidence. A drug also used in cancer care went into a documented oral-tablet shortage during the surge. The roughly 70 children who genuinely have CFD-FOLR1 — who legitimately benefit from the drug — risk having their approved treatment obscured by the wider controversy. Dr. Richard Frye and the folate supplement ecosystem around him benefit from sustained public interest in folate treatments for autism, regardless of the underlying clinical evidence. ^[19][25]

Makary's broader FDA agenda under the MAHA umbrella includes pushing to phase out artificial food dyes, targeting ultra-processed foods, and reviewing more than 11,000 chemicals used in U.S. food that are restricted elsewhere. Some of these priorities carry genuine scientific support — but the leucovorin episode illustrates how the same apparatus can generate misinformation and real supply strain when a political announcement runs ahead of the underlying regulatory review. ^[9][10]

The leucovorin episode is a case study in what happens when the institutional apparatus for building public trust in medicine outpaces its own evidence. The FDA Commissioner's office exists to translate the outputs of clinical science into public health guidance. When that office makes a claim that turns out to be roughly 3,500 times larger than what its own review ultimately supported — from a White House podium, alongside the President — the resulting confusion is qualitatively different from the everyday flow of health misinformation online.

The counterfactual matters: had Makary announced in September 2025 that the FDA was considering a narrow label change for a genetic condition affecting roughly 70 children in the United States, the documented 71% prescription surge, the oral-tablet supply strain, and the emergency imports from Canada and Spain would likely have been far smaller or avoided entirely. The children with actual CFD-FOLR1 would still have received their genuinely beneficial approval, without the surrounding noise. ^[4]

Instead, Makary announced the maximum possible version of an outcome that had not yet been determined, using numbers his own agency's review would not ultimately support, to an audience of families desperate for hope. The resulting prescribing surge was documented in a peer-reviewed journal at 71% above baseline. FactCheck.org — writing in direct response to the FDA Commissioner's own prior statements — titled its analysis "No Broad Autism Approval for Leucovorin, Despite FDA Commissioner's Prior Suggestions." ^[1][3]

The verdict is MISLEADING: not because the underlying science was fabricated by Makary, but because a sitting FDA Commissioner, from an official platform, quantified a benefit at a scale his own agency's subsequent review did not support — a gap large enough, and consequential enough in prescribing behavior and drug supply, to constitute misleading public communication rather than mere imprecision. The roughly 70 children who genuinely have CFD-FOLR1 deserve the treatment that was approved; the millions of autistic children in the United States and their families deserved a more accurate account of the evidence from the start. ^[1][3][13]